22 Hrs
Source:
Financial Times
AstraZeneca Focuses on Rare Diseases in $80bn Growth
The chief executive of Alexion stated that the market for rare disease medicines remains largely underdeveloped and presents significant growth opportunities.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)